Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Capital Expenditures (2016 - 2025)

Catalyst Pharmaceuticals' Capital Expenditures history spans 12 years, with the latest figure at $32000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 63.64% year-over-year to $32000.0; the TTM value through Dec 2025 reached $58000.0, down 89.57%, while the annual FY2025 figure was $58000.0, 89.57% down from the prior year.
  • Capital Expenditures reached $32000.0 in Q4 2025 per CPRX's latest filing, up from $26000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $911000.0 in Q1 2021 to a low of $1000.0 in Q2 2021.
  • Average Capital Expenditures over 4 years is $143538.5, with a median of $68000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: surged 304.69% in 2024, then tumbled 63.64% in 2025.
  • A 4-year view of Capital Expenditures shows it stood at $41000.0 in 2021, then surged by 126.83% to $93000.0 in 2023, then dropped by 5.38% to $88000.0 in 2024, then crashed by 63.64% to $32000.0 in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Capital Expenditures are $32000.0 (Q4 2025), $26000.0 (Q2 2025), and $88000.0 (Q4 2024).